Optimizing treatment for HER2-positive HR-positive breast cancer

被引：3

作者：

Debien, Veronique ^{[1
]}

de Azambuja, Evandro ^{[1
]}

Piccart-Gebhart, Martine ^{[2
,3
]}

机构：

[1] Univ Libre Bruxelles ULB, Hop Univ Bruxelles HUB, Inst Jules Bordet, Acad Trials Promoting Team, Brussels, Belgium

[2] Univ Libre Bruxelles ULB, Hop Univ Bruxelles HUB, Inst Jules Bordet, Brussels, Belgium

[3] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Dept, Rue Meylemeersch 90, B-1070 Anderlecht, Belgium

来源：

CANCER TREATMENT REVIEWS | 2023年 / 115卷

关键词：

HER2-positive breast cancer; Anti-HER2; therapy; Monoclonal antibody; Tyrosine kinase inhibitor; Antibody -drug conjugate; Endocrine therapy; Clinical trials; Biomarkers; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; TRASTUZUMAB EMTANSINE; DOUBLE-BLIND; PHASE-III; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; RANDOMIZED MULTICENTER; ADJUVANT CHEMOTHERAPY; TAMOXIFEN RESISTANCE;

D O I：

10.1016/j.ctrv.2023.102529

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-positive breast tumors overexpress human epidermal growth factor receptor 2 (HER2) and are positive for hormone receptor (HR) expression. Data from real-life and clinical trials show that estrogen receptor (ER) expression affects the response to combinations of anti-HER2 and associated systemic therapies. Despite triple -positive tumors having decreased response rates compared to HR-negative/HER2-positive breast cancers, opti-mizing anti-HER2 treatment with dual anti-HER2 blockade remains important for optimal disease control. Preclinical data on the cross-talk between ER and growth factor receptor pathways show the efficacy of com-binations of endocrine therapy and anti-HER2 drugs, which is confirmed in the clinic. Molecular dissection of triple-positive breast cancer might provide the rational for additional therapeutic strategies and the identification of promising biomarkers. This review summarizes data on systemic treatment efficacy from major clinical trials and perspectives for future clinical research in triple-positive breast cancer.

引用

页数：16

共 50 条

[31] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
Nardin, Simone
Del Mastro, Lucia
ANNALS OF TRANSLATIONAL MEDICINE, 2023,
[32] Ribociclib for HR-Positive, Advanced Breast Cancer
De Gramont, Armand
Herrera, Alain
de Gramont, Aimery
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 288 - 289
[33] Everolimus Approved for HR-Positive Breast Cancer
不详
CANCER DISCOVERY, 2012, 2 (09) : 756 - 756
[34] Updates in Treatment of HER2-positive Metastatic Breast Cancer
Alzira R. M. Avelino
Soumya Pulipati
Kevin Jamouss
Prarthna V. Bhardwaj
Current Treatment Options in Oncology, 2024, 25 (12) : 1471 - 1481
[35] The changing treatment of metastatic her2-positive breast cancer
Mitsogianni, Maria
Trontzas, Ioannis P.
Gomatou, Georgia
Ioannou, Stephanie
Syrigos, Nikolaos K.
Kotteas, Elias A.
ONCOLOGY LETTERS, 2021, 21 (04)
[36] Role of pertuzumab in the treatment of HER2-positive breast cancer
Hubalek, Michael
Brantner, Christine
Marth, Christian
BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 65 - 73
[37] Margetuximab for the treatment of HER2-positive metastatic breast cancer
Tarantino, Paolo
Morganti, Stefania
Uliano, Jacopo
Giugliano, Federica
Crimini, Edoardo
Curigliano, Giuseppe
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
[38] HER2-positive breast cancer: Current treatment strategies
Perez, Edith A.
Baweja, Mansoina
CANCER INVESTIGATION, 2008, 26 (06) : 545 - 552
[39] New developments in the treatment of HER2-positive breast cancer
Nahta, Rita
BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 53 - 64
[40] Treatment of brain metastases of HER2-positive breast cancer
Heudel, P.
Tredan, O.
Cassier, P.
Ray-Coquard, I.
Guastalla, J. -P.
Bachelot, T.
ONCOLOGIE, 2012, 14 (01) : 41 - 44

← 1 2 3 4 5 →